Castle Biosciences, Inc. (CSTL) Q2 2020 Earnings Results

Castle Biosciences, Inc. Beats on EPS, Stock Down 0.62%

Castle Biosciences reported a narrower-than-expected loss per share, which is a positive surprise for investors. However, the stock reacted negatively, declining by 0.62%. The lack of revenue figures and management commentary may have contributed to the stock's downward movement.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.08	N/A	+80.72%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

Castle Biosciences, Inc. Beats on EPS, Stock Down 0.62%

Key numbers

Management commentary

Castle Biosciences, Inc.

More earnings this week

Castle Biosciences, Inc. Beats on EPS, Stock Down 0.62%

Key numbers

Management commentary